Individuals who should not take semaglutide are:Those with multiple endocrine neoplasia type 2 (MEN2),medullary thyroid cancer,diabetic ketoacidosis (DKA)
Mozart Therapeutics Showcases Preliminary Data for Key Project, MTX-101, Aimed at Autoimmune Condition Management, at the 2024 Society of Toxicology Gathering.
On February 28th, US-based Viatris and Swiss firm Idorsia launched a major R&D partnership, with Viatris securing exclusive global rights for two Phase 3 drugs, Selatogrel and Cenerimod, and options for future joint projects.
Madrigal Pharmaceuticals Reveals Rezdiffra™ (resmetirom) Gets Green Light from FDA to Manage Noncirrhotic NASH Sufferers with Moderate to Severe Fibrotic Liver Conditions.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that plays a multifaceted role in managing type 2 diabetes and promoting weight loss.
FDA Grants Authorization for Mirum Pharmaceuticals' Drug LIVMARLI to Treat Itchy Skin Caused by Bile Buildup in Individuals with Advanced Hereditary Liver Disorder.